Using a synergy of additional PD-L1 checkpoint blockade achieved the most significant abscopal effect – with treatments of “CFP+anti-PD-L1” and “CFP + US+anti-PD-L1” resulting in an outstanding suppression on primary tumour growth, with a tumour growth inhibition of 46.7% and 66.3%, respectively. The gene discussed is CD274; the disease is neoplasm.